A member of HemoGenyx Pharmaceuticals PLC’s (LON:HEMO) scientific advisory board has received the American scientific equivalent to the Nobel Prize.
H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been recognised with the 2019 Lasker-DeBakey Clinical Medical Research Award.
The Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life”.
Hemogenyx chief executive Vladislav Sandler said: "We are thrilled that Dr Shepard's life-saving work has been recognised by this prestigious award and we are fortunate to have such a distinguished scientist advising our own organisation's cutting-edge cancer research."